• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Is it true?

anonymous

Guest
Is Tegaserod (Zelnorm) coming back? Heard from a physician the other day that the efficacy of Tegaserod was much better than Amatiza and physicians across the country are requesting data that has yet to be released. If Zelnorm arises from the grave, maybe this time the brand team and management will not suggest "off-label" uses for that which is not approved.